Advertisement

Journal of Neuro-Oncology

, Volume 75, Issue 2, pp 215–220 | Cite as

Systemic Temozolomide Combined with Loco-regional Mitoxantrone in Treating Recurrent Glioblastoma

  • A. Boiardi
  • M. Eoli
  • A. Salmaggi
  • E. Lamperti
  • A. Botturi
  • G. Broggi
  • L. Bissola
  • G. Finocchiaro
  • A. Silvani
Clinical Study

Abstract

Twenty-two recurrent GBM patients were enrolled for second tumor debulking with local positioning of a Rickam reservoir, in order to locally deliver chemotherapy with the aim of controlling local tumor recurrence. We designed a protocol using systemic temozolomide (150 mg/sqm days 1–5 every 28) in association with mitoxantrone, delivered through the reservoir (4 mg/day 1–5 every 28) positioned into the area of tumor exeresis. After re-operation a residual tumor mass no larger than 2 cm was identified in 18/22 patients. The patients were treated with monthly cycles of chemotherapy until evolution of the tumor, but in no case for more than 10 cycles. Responses were evaluated by MRI scans performed every 2 months and images assessed according to MacDonald’s criteria. Response rate: no complete responses (CR), 5 partial responses (PR), 13 stable disease (SD) and 4 progressive disease (PD) occurred. The median progression-free survival (PFS) and survival time (ST) of the whole group of treated patients was 7 and 11 months, respectively and more than a quarter of the patients survived over 18 months. During the study, the patients’ compliance was complete and no dropouts occurred. Hematological toxicity was mild and after repeated local injections only minor neurological side-effects occurred. Despite some bias in patients’ selection not excluded in this pilot study, results are interesting: the PFS was as long as the survival of recurrent GBM reported in the literature.

Keywords

loco-regional chemotherapy mitoxantrone recurrent glioblastoma Rickam reservoir temozolomide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Huncharek, M, Muscat, J 1998Treatment of recurrent high grade astrocytoma: results of a systematic review of 1415 patientsAnticancer Res1813031312PubMedGoogle Scholar
  2. 2.
    Kornblith, PL, Walker, M 1998Chemotherapy for malignant gliomasJ Neurosurg68117Google Scholar
  3. 3.
    Walker, MD, Green, SB, Byar, DP, Alexander, E,Jr, Batzdorf, U, Brooks, WH, Hunt, WE, McCarty, CS, Mahavley, MS,Jr, Mealey, J, Owens, G, Ransohoff, J, Robertson, JT 1980Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgeryN Engl J Med30313231327PubMedGoogle Scholar
  4. 4.
    Fine, HA, Dear, KBG, Loeffler, YS, Black, PML, Canellos, GP 1993Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adultsCancer7125852597PubMedGoogle Scholar
  5. 5.
    Yung, WK, Albright, RE, Olson, J, Fredericks, R, Fink, K, Prados, MD, Brada, M, Spence, A, Hohl, RJ, Shapiro, W, Glantz, M, Greenberg, H, Selker, RG, Vick, NA, Rampling, R, Friedman, H, Phillips, P, Bruner, J, Yue, N, Osoba, D, Zaknoen, S, Levin, VA 2000A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforne at first relapseBr J Cancer83588593CrossRefPubMedGoogle Scholar
  6. 6.
    Osoba, D, Brada, M, Prados, MD, Yung, WK 2000Effect of disease burden on health-related quality of life in patients with malignant gliomasNeuro-oncol4221228CrossRefGoogle Scholar
  7. 7.
    Brada, M, Hoang-Xuan, K, Rampling, R, Dietrich, PY, Dirix, LY, MacDonald, D, Heimans, JJ, Zonnenberg, BA, Bravo-Marques, JM, Henriksson, R, Stupp, R, Yue, N, Bruner, J, Dugan, M, Rao, S, Zaknoen, S 2001Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapseAnn Oncol12149150CrossRefPubMedGoogle Scholar
  8. 8.
    McDonald, DR 2001Temozolomide for recurrent high-grade gliomaSemin Oncol4312Google Scholar
  9. 9.
    Sipos, L, Vitanovics, D, Afra, D 2001Treatment of recidive malignant gliomas with temozolomideAnn Oncol12259266CrossRefPubMedGoogle Scholar
  10. 10.
    Gaya, A, Rees, J, Greenstein, A, Stebbing, J 2002The use of temozolomide in recurrent malignant gliomasCancer Treat Rev28115120CrossRefPubMedGoogle Scholar
  11. 11.
    Trent, S, Kong, A, Short, SC, Traish, D, Ashley, S, Dowe, A, Hines, F, Brada, M 2002Temozolomide as second-line chemotherapy for relapsed gliomasJ Neurooncol57247251CrossRefPubMedGoogle Scholar
  12. 12.
    Prados, M 2001Temozolomide in combination with other cytotoxic agentsSemin Oncol282433CrossRefGoogle Scholar
  13. 13.
    Newlands, ES, Foster, T, Zaknoen, S 2003Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomasBr J Cancer21248251CrossRefGoogle Scholar
  14. 14.
    Korones, DN, Benita-Weiss, M, Coyle, TE, Mechtler, L, Bushunow, P, Evans, B, Reardon, DA, Quinn, JA, Friedman, H 2003Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant gliomaCancer9719631968CrossRefPubMedGoogle Scholar
  15. 15.
    Groves, MD, Puduvalli, VK, Hess, KR, Jaeckle, KA, Peterson, P, Yung, WK, Levin, VA 2002Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiformeClin Oncol2013831388CrossRefGoogle Scholar
  16. 16.
    Tolcher, AW, Gerson, SL, Denis, L, Geyer, C, Hammond, LA, Patnaik, A, Goetz, AD, Schwartz, G, Edwards, T, Reyderman, L, Statkevich, P, Cutler, DL, Rowinsky, EK 2003Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBr J Cancer8810041011CrossRefPubMedGoogle Scholar
  17. 17.
    Khan, RB, Raizer, JJ, Malkin, MG, Bazylewicz, KA, Abrey, LE 2002A phase II study of extended low-dose temozolomide in recurrent malignant gliomasNeuro-oncol43943CrossRefPubMedGoogle Scholar
  18. 18.
    Esteller, M, Hamilton, SR, Burger, PC, Baylin, SB, Herman, JG 1999Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasiaCancer Res59793797PubMedGoogle Scholar
  19. 19.
    Nakamura, M, Watanabe, T, Yonekawa, Y, Kleihues, P, Ohgaki, H 2001Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C –> A:T mutations of the TP53 tumor suppressor geneCarcinogenesis2217151719CrossRefPubMedGoogle Scholar
  20. 20.
    Gururangan, S, Cokgor, L, Rich, JN, Edwards, S, Affronti, ML, Quinn, JA, Herndon, JE,2nd, Provenzale, JM, McLendon, RE, Tourt-Uhlig, S, Sampson, JH, Stafford-Fox, V, Zaknoen, S, Early, M, Friedman, AH, Friedman, HS 2001Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomasNeuro-oncol3246250CrossRefPubMedGoogle Scholar
  21. 21.
    Boiardi, A, Silvani, A, Pozzi, AL, Fariselli, L, Broggi, G, Salmaggi, G 1999Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studiesJ Neuroncol41151157CrossRefGoogle Scholar
  22. 22.
    Boiardi, A, Eoli, M, Salmaggi, A, Zappacosta, B, Fariselli, L, Milanesi, I, Broggi, G, Silvani, A 2001Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumoursJ Neurooncol543947CrossRefPubMedGoogle Scholar
  23. 23.
    MacDonald, DR, Cascino, TL, Clifford, S 1990Response criteria for phase II studies of supratentorial malignant gliomaJ Clin Oncol812771280PubMedGoogle Scholar
  24. 24.
    Bissola L, Eoli M, Silvani A, Polio B, Bianchissi D, Manghi F, Boiardi A, Finocchiaro G: MGMT promoter hypermethylation is more frequent in secondary GBM and is independent from other prognostic factor. Proceedings of the American association for Cancer research 95. Annual meeting 2004. Orlando, FLGoogle Scholar
  25. 25.
    Kaplan, EL, Meier, P 1958Nonparametric estimation from incomplete observationsJ Am Stat Assoc53457481Google Scholar
  26. 26.
    Oken, MM, Creech, RH, Tormey, DC, Horton, J, Davis, TE, McFadden, ET, Carbone, PP 1982Toxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol5649655PubMedGoogle Scholar
  27. 27.
    Gilbert, MR, Supko, JG, Batchelor, T, Lesser, G, Fisher, JD, Piantadosi, S, Grossman, S 2003Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant gliomaClin Cancer Res929402949PubMedGoogle Scholar
  28. 28.
    Ermani M, Brandes A, Pasetto LM, Basso U, Reni M, Turazzi S, Berlucchi S, Ruzzolino P, Pinna G, Scienza R. Monfardini S, First line chemotherapy with cisplatin plus fractionated temozolomide [bid] in recurrent glioblastoma (GBM). Annual Meeting ASCO abs 2076. Orlando, 2000Google Scholar
  29. 29.
    Korones, DN, Benita-Weiss, M, Coyle, TE, Mechtler, L, Bushunow, P, Evans, B, Reardon, DA, Quinn, JA, Friedman, H 2003Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant gliomaCancer1519631968CrossRefGoogle Scholar
  30. 30.
    Brem, H, Piantadossi, S, Burger, P, Walker, M, Seiler, RW 1995Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain Tumor Treatment GroupLancet34510081012CrossRefPubMedGoogle Scholar
  31. 31.
    Valtonen, S, Timonen, U, Toivanen, P, Kalimo, H, Kivipelto, L, Heiskanen, O, Usgaard, G, Kuurne, T 1997Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind studyNeurosurgery414449CrossRefPubMedGoogle Scholar
  32. 32.
    Sipos, EP, Tyler, B, Piantadosi, S, Burger, PC, Brem, H 1997Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumorsCancer Chemother Pharmacol39383389CrossRefPubMedGoogle Scholar
  33. 33.
    Perego, P, Boiardi, A, Carenini, N, Cesare, M, Dolfini, E, Giardino, R, Magnani, I, Silvani, A, Soranzo, C 1994Characterisation of an established human maligant glioblastoma cell line and its response to conventional garugsJ Cancer Res Clin Oncol120585592CrossRefPubMedGoogle Scholar
  34. 34.
    Jordan, JP, Hand, CM, Markowitz, RS, Black, P 1992Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assayJ Neurooncol141935CrossRefPubMedGoogle Scholar
  35. 35.
    Nikkhah, G, Tonn, JC, Hoffmann, O, Kraemer, HP, Darling, JL, Schachenmayr, W, Schonmayr, R 1992The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variablesJ Neurooncol131324PubMedGoogle Scholar
  36. 36.
    Senkal, M, Tonn, JC, Schonmayr, R, Schachenmayr, W, Eickhoff, U, Kelnen, M, Kollig, E 1997Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumorsJ Neurooncol32203208CrossRefPubMedGoogle Scholar
  37. 37.
    Green, RM, Stewart, DJ, Hugenholtz, H, Richard, MT, Thibault, M, Montpetit, V 1986Human central nervous system and plasma pharmacology of mitoxantroneJ Neurooncol67583CrossRefGoogle Scholar
  38. 38.
    Wolff, JE, Trilling, T, Molenkamp, G, Egeler, RM, Jurgens, H 1999Chemosensitivity of glioma cells in vitro: a meta analysisJ Cancer Res Clin Oncol125481486CrossRefPubMedGoogle Scholar
  39. 39.
    Stewart, DJ, Green, RM, Mikhael, NZ, Montpetit, V, Thibault, M, Maroun, JA 1986Human autopsy tissue concentrations of mitoxantroneCancer Treat Rep7012551261PubMedGoogle Scholar
  40. 40.
    Di Meco, F, Li, KW, Tyler, BM, Wolf, AS, Brem, H, Olivi, A 2002Local delivery of mitoxantrone for the treatment of malignant brain tumors in ratsJ Neurosurg511731178Google Scholar
  41. 41.
    Kroll, RA, Pagel, MA, Muldoon, LL, Roman-Goldstein, S, Neuwelt, E 1996Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factorNeurosurgery38746753CrossRefPubMedGoogle Scholar
  42. 42.
    Broggi, G, Ferroli, P, Franzini, A, Silvani, A, Salmaggi, A, Eoli, M, Boiardi, A 2003Local delivery of mitoxantrone for the treatment of malignant brain tumors in ratsJ Neurosurg98935936PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • A. Boiardi
    • 1
  • M. Eoli
    • 1
  • A. Salmaggi
    • 1
  • E. Lamperti
    • 1
  • A. Botturi
    • 1
  • G. Broggi
    • 2
  • L. Bissola
    • 3
  • G. Finocchiaro
    • 3
  • A. Silvani
    • 1
  1. 1.Department of Neuro-OncologyIstituto Nazionale Neurologico “Carlo Besta”Italy
  2. 2.Department of NeurosurgeryIstituto Nazionale Neurologico “Carlo Besta”Italy
  3. 3.Unit of Experimental Neuro-Oncology and Gene Therapy Istituto Nazionale Neurologico “Carlo Besta”MilanoItaly

Personalised recommendations